{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:14:32Z","timestamp":1793816072631,"version":"4.6.1"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["11L5124N"],"award-info":[{"award-number":["11L5124N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by a deficiency of the L-phenylalanine-4-hydroxylase enzyme or its cofactor tetrahydrobiopterin (BH4) resulting in increased levels of phenylalanine (Phe) in blood and cerebrospinal fluid. Symptoms include hypopigmentation, a musty, mouse-like smell and various neurological complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main text<\/jats:title>\n            <jats:p>Treatment options include (i) dietary restriction of Phe with supplementation of other amino acids and micronutrients through medical mixtures, (ii) daily dosing of large neutral amino acids, (iii) synthetic forms of BH4 and (iv) bacterial phenylalanine ammonia lyase enzymes. The primary goal of treatment is to lower blood Phe levels and improve quality of life. However, treatment is very demanding for patients as well as their families, and not all treatment options are applicable to every patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This review gives a state-of-the-art overview of current treatment options for all PKU patients and additionally speculates on future therapeutic approaches.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03840-y","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:01:00Z","timestamp":1749142860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Current state of the treatment landscape of phenylketonuria"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9966-1340","authenticated-orcid":false,"given":"Ine","family":"Nulmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sien","family":"Lequeue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Desmet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Neuckermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joery","family":"De Kock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"2","key":"3840_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","volume":"107","author":"A Hillert","year":"2020","unstructured":"Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, et al. The genetic landscape and epidemiology of phenylketonuria. Am J Hum Genet. 2020;107(2):234\u201350.","journal-title":"Am J Hum Genet"},{"issue":"1\u20134","key":"3840_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1515\/bchm2.1934.227.1-4.169","volume":"227","author":"A F\u00f6lling","year":"1934","unstructured":"F\u00f6lling A. \u00dcber ausscheidung von phenylbrenztraubens\u00e4ure in Den Harn Als stoffwechselanomalie in verbindung Mit imbezillit\u00e4t. Hoppe Seylers Z Physiol Chem. 1934;227(1\u20134):169\u201381.","journal-title":"Hoppe Seylers Z Physiol Chem"},{"issue":"s407","key":"3840_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1651-2227.1994.tb13440.x","volume":"83","author":"I F\u00f8lling","year":"1994","unstructured":"F\u00f8lling I. The discovery of phenylketonuria. Acta Paediatr. 1994;83(s407):4\u201310.","journal-title":"Acta Paediatr"},{"issue":"8","key":"3840_CR4","doi-asserted-by":"publisher","first-page":"e0201489","DOI":"10.1371\/journal.pone.0201489","volume":"13","author":"P Gundorova","year":"2018","unstructured":"Gundorova P, Zinchenko RA, Kuznetsova IA, Bliznetz EA, Stepanova AA, Polyakov AV. Molecular-genetic causes for the high frequency of phenylketonuria in the population from the North Caucasus. PLoS ONE. 2018;13(8):e0201489.","journal-title":"PLoS ONE"},{"issue":"1","key":"3840_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","volume":"7","author":"FJ van Spronsen","year":"2021","unstructured":"van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM, Phenylketonuria. Nat Rev Dis Primers. 2021;7(1):36.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3840_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13023-021-01874-6","volume":"16","author":"PK Foreman","year":"2021","unstructured":"Foreman PK, Margulis AV, Alexander K, Shediac R, Calingaert B, Harding A, et al. Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis. Orphanet J Rare Dis. 2021;16(1):253.","journal-title":"Orphanet J Rare Dis"},{"issue":"20","key":"3840_CR7","doi-asserted-by":"publisher","first-page":"12127","DOI":"10.1109\/JSEN.2020.3008613","volume":"20","author":"H Arslan","year":"2020","unstructured":"Arslan H, Unal K, Aynaci Koyuncu E, Yildirim E, Arslan F. Development of a novel phenylalanine biosensor for diagnosis of phenylketonuria. IEEE Sens J. 2020;20(20):12127\u201333.","journal-title":"IEEE Sens J"},{"issue":"1","key":"3840_CR8","first-page":"59","volume":"55","author":"C Carducci","year":"2020","unstructured":"Carducci C, Amayreh W, Ababneh H, Mahasneh A, Al Rababah B, Al Qaqa K, et al. Molecular genetics of phenylketonuria and tetrahydrobiopterin deficiency in Jordan. JIMD Rep. 2020;55(1):59\u201367.","journal-title":"JIMD Rep"},{"issue":"9750","key":"3840_CR9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau N, van Spronsen FJ, Levy HL. Phenylketonuria Lancet. 2010;376(9750):1417\u201327.","journal-title":"Phenylketonuria Lancet"},{"issue":"8","key":"3840_CR10","doi-asserted-by":"publisher","first-page":"e0183430","DOI":"10.1371\/journal.pone.0183430","volume":"12","author":"E Fiori","year":"2017","unstructured":"Fiori E, Oddi D, Ventura R, Colamartino M, Valzania A, D\u2019Amato FR, et al. Early-onset behavioral and neurochemical deficits in the genetic mouse model of phenylketonuria. PLoS ONE. 2017;12(8):e0183430.","journal-title":"PLoS ONE"},{"issue":"5","key":"3840_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/pcmr.12393","volume":"28","author":"M d\u2019Ischia","year":"2015","unstructured":"d\u2019Ischia M, Wakamatsu K, Cicoira F, Di Mauro E, Garcia-Borron JC, Commo S, et al. Melanins and melanogenesis: from pigment cells to human health and technological applications. Pigment Cell Melanoma Res. 2015;28(5):520\u201344.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9","key":"3840_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2010.125","volume":"6","author":"FJ van Spronsen","year":"2010","unstructured":"van Spronsen FJ. Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol. 2010;6(9):509\u201314.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"3840_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF01054531","volume":"67","author":"JD Lane","year":"1980","unstructured":"Lane JD, Neuhoff V, Phenylketonuria. Sci Nat. 1980;67(5):227\u201333.","journal-title":"Sci Nat"},{"issue":"6","key":"3840_CR14","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S0022-3476(64)80641-7","volume":"64","author":"SP Bessman","year":"1964","unstructured":"Bessman SP. Some biochemical lessons to be learned from phenylketonuria. J Pediatr. 1964;64(6):828\u201338.","journal-title":"J Pediatr"},{"issue":"5","key":"3840_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.14336\/AD.2015.0827","volume":"6","author":"P Schuck","year":"2015","unstructured":"Schuck P, Malgarin F, Cararo J, Cardoso F, Streck E, Ferreira G. Phenylketonuria pathophysiology: on the role of metabolic alterations. Aging Dis. 2015;6(5):390.","journal-title":"Aging Dis"},{"issue":"2","key":"3840_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ymgme.2022.03.012","volume":"136","author":"SF Dobrowolski","year":"2022","unstructured":"Dobrowolski SF, Phua YL, Vockley J, Goetzman E, Blair HC. Phenylketonuria oxidative stress and energy dysregulation: emerging pathophysiological elements provide interventional opportunity. Mol Genet Metab. 2022;136(2):111\u20137.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3840_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00415-019-09608-2","volume":"267","author":"P Jaulent","year":"2020","unstructured":"Jaulent P, Charriere S, Feillet F, Douillard C, Fouilhoux A, Thobois S. Neurological manifestations in adults with phenylketonuria: new cases and review of the literature. J Neurol. 2020;267(2):531\u201342.","journal-title":"J Neurol"},{"issue":"8","key":"3840_CR18","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1172\/JCI5017","volume":"103","author":"J Pietz","year":"1999","unstructured":"Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999;103(8):1169\u201378.","journal-title":"J Clin Invest"},{"issue":"2","key":"3840_CR19","first-page":"188","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Sci. 2014;16(2):188\u2013200.","journal-title":"Genet Sci"},{"issue":"3","key":"3840_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymgme.2021.01.014","volume":"132","author":"SF Dobrowolski","year":"2021","unstructured":"Dobrowolski SF, Sudano C, Phua YL, Tourkova IL, Spridik K, Goetzman ES, et al. Mesenchymal stem cell energy deficit and oxidative stress contribute to osteopenia in the Pahenu2 classical PKU mouse. Mol Genet Metab. 2021;132(3):173\u20139.","journal-title":"Mol Genet Metab"},{"key":"3840_CR21","doi-asserted-by":"publisher","first-page":"115881","DOI":"10.1016\/j.bone.2021.115881","volume":"146","author":"A Suzuki","year":"2021","unstructured":"Suzuki A, Iwata J. Amino acid metabolism and autophagy in skeletal development and homeostasis. Bone. 2021;146:115881.","journal-title":"Bone"},{"issue":"1","key":"3840_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ymgme.2022.03.004","volume":"136","author":"SF Dobrowolski","year":"2022","unstructured":"Dobrowolski SF, Phua YL, Sudano C, Spridik K, Zinn PO, Wang Y, et al. Comparative metabolomics in the Pahenu2 classical PKU mouse identifies cerebral energy pathway disruption and oxidative stress. Mol Genet Metab. 2022;136(1):38\u201345.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"3840_CR23","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1007\/s12035-021-02304-1","volume":"58","author":"ATS Wyse","year":"2021","unstructured":"Wyse ATS, dos Santos TM, Seminotti B, Leipnitz G. Insights from animal models on the pathophysiology of hyperphenylalaninemia: role of mitochondrial dysfunction, oxidative stress and inflammation. Mol Neurobiol. 2021;58(6):2897\u2013909.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"3840_CR24","doi-asserted-by":"publisher","first-page":"15020","DOI":"10.1038\/boneres.2015.20","volume":"3","author":"DJ Lee","year":"2015","unstructured":"Lee DJ, Tseng HC, Wong SW, Wang Z, Deng M, Ko CC. Dopaminergic effects on in vitro osteogenesis. Bone Res. 2015;3(1):15020.","journal-title":"Bone Res"},{"issue":"4","key":"3840_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/humu.23707","volume":"40","author":"R Scheller","year":"2019","unstructured":"Scheller R, Stein A, Nielsen SV, Marin FI, Gerdes A, Marco M, et al. Toward mechanistic models for genotype\u2013phenotype correlations in phenylketonuria using protein stability calculations. Hum Mutat. 2019;40(4):444\u201357.","journal-title":"Hum Mutat"},{"issue":"3","key":"3840_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/ejhg.2014.114","volume":"23","author":"S Wettstein","year":"2015","unstructured":"Wettstein S, Underhaug J, Perez B, Marsden BD, Yue WW, Martinez A, et al. Linking genotypes database with locus-specific database and genotype\u2013phenotype correlation in phenylketonuria. Eur J Hum Genet. 2015;23(3):302\u20139.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"3840_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/humu.22980","volume":"37","author":"N Blau","year":"2016","unstructured":"Blau N. Genetics of phenylketonuria: then and now. Hum Mutat. 2016;37(6):508\u201315.","journal-title":"Hum Mutat"},{"issue":"1\u20132","key":"3840_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ymgme.2018.06.011","volume":"125","author":"N Himmelreich","year":"2018","unstructured":"Himmelreich N, Shen N, Okun JG, Thiel C, Hoffmann GF, Blau N. Relationship between genotype, phenylalanine hydroxylase expression and in vitro activity and metabolic phenotype in phenylketonuria. Mol Genet Metab. 2018;125(1\u20132):86\u201395.","journal-title":"Mol Genet Metab"},{"issue":"6790","key":"3840_CR29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S0140-6736(53)90473-5","volume":"262","author":"H Bickel","year":"1953","unstructured":"Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenylketonuria. Lancet. 1953;262(6790):812\u20133.","journal-title":"Lancet"},{"issue":"1","key":"3840_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1651-2227.1954.tb04000.x","volume":"43","author":"H BICKEL","year":"1954","unstructured":"BICKEL H, GERRARD J. The influence of phenylalanine intake on the chemistry and behaviour of a phenylketonuria child. Acta Paediatr. 1954;43(1):64\u201377.","journal-title":"Acta Paediatr"},{"issue":"3","key":"3840_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1542\/peds.32.3.338","volume":"32","author":"R Guthrie","year":"1963","unstructured":"Guthrie R, Susi A, A SIMPLE PHENYLALANINE METHOD FOR DETECTING, PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS. Pediatrics. 1963;32(3):338\u201343.","journal-title":"Pediatrics"},{"issue":"1","key":"3840_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg AMJ, MacDonald A, Ahring K, B\u00e9langer-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3840_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/clinchem\/39.1.66","volume":"39","author":"DH Chace","year":"1993","unstructured":"Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem. 1993;39(1):66\u201371.","journal-title":"Clin Chem"},{"issue":"9","key":"3840_CR34","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2010.271","volume":"48","author":"V De Silva","year":"2010","unstructured":"De Silva V, Oldham CD, May SW. L-Phenylalanine concentration in blood of phenylketonuria patients: a modified enzyme colorimetric assay compared with amino acid analysis, tandem mass spectrometry, and HPLC methods. Cclm. 2010;48(9):1271\u20139.","journal-title":"Cclm"},{"issue":"2","key":"3840_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/00313020701813743","volume":"40","author":"B Wilcken","year":"2008","unstructured":"Wilcken B, Wiley V. Newborn screening. Pathology. 2008;40(2):104\u201315.","journal-title":"Pathology"},{"issue":"3","key":"3840_CR36","first-page":"230","volume":"13","author":"DMS McHugh","year":"2011","unstructured":"McHugh DMS, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. Genet Sci. 2011;13(3):230\u201354.","journal-title":"Genet Sci"},{"key":"3840_CR37","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ymgme.2011.08.017","volume":"104","author":"N Blau","year":"2011","unstructured":"Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011;104:S2\u20139.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"3840_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10545-012-9506-x","volume":"35","author":"T Opladen","year":"2012","unstructured":"Opladen T, Hoffmann GF, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis. 2012;35(6):963\u201373.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3840_CR39","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/ajcn\/64.6.916","volume":"64","author":"F van Spronsen","year":"1996","unstructured":"van Spronsen F, van Dijk T, Smit G, van Rijn M, Reijngoud D, Berger R, et al. Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr. 1996;64(6):916\u201321.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"3840_CR40","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1542\/peds.92.4.570","volume":"92","author":"FJ van Spronsen","year":"1993","unstructured":"van Spronsen FJ, van Rijn M, van Dijk T, Smit GP, Reijngoud DJ, Berger R, et al. Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting\/postprandial) in patients with phenylketonuria: effect of sample timing. Pediatrics. 1993;92(4):570\u20133.","journal-title":"Pediatrics"},{"key":"3840_CR41","unstructured":"Shapira E, Blitzer MG, Miller J, Africk DK. Biochemical genetics: A laboratory manual. J Med Genet. 1989;27(5)."},{"issue":"11","key":"3840_CR42","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/adc.49.11.835","volume":"49","author":"ME Blaskovics","year":"1974","unstructured":"Blaskovics ME, Schaeffler GE, Hack S. Phenylalaninaemia: differential diagnosis. Arch Dis Child. 1974;49(11):835\u201343.","journal-title":"Arch Dis Child"},{"issue":"3","key":"3840_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/jmedgenet-2014-102621","volume":"52","author":"MK Danecka","year":"2015","unstructured":"Danecka MK, Woidy M, Zschocke J, Feillet F, Muntau AC, Gersting SW. Mapping the functional landscape of frequent phenylalanine hydroxylase (PAH) genotypes promotes personalised medicine in phenylketonuria. J Med Genet. 2015;52(3):175\u201385.","journal-title":"J Med Genet"},{"issue":"S2","key":"3840_CR44","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1007\/PL00014382","volume":"159","author":"J Zschocke","year":"2000","unstructured":"Zschocke J, Hoffmann GF. PAH gene mutation analysis in clinical practice \u2013 comments on mutation analysis anticipates dietary requirements in phenylketonuria. Eur J Pediatr. 2000;159(S2):S154\u20135.","journal-title":"Eur J Pediatr"},{"key":"3840_CR45","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16\u201318, 2000. Pediatrics. 2001;108(4):972\u201382.","DOI":"10.1542\/peds.108.4.972"},{"issue":"7","key":"3840_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1017\/S0012162205000861","volume":"47","author":"R Gassi\u00f3","year":"2005","unstructured":"Gassi\u00f3 R, Artuch R, Vilaseca MA, Fust\u00e9 E, Boix C, Sans A, et al. Cognitive functions in classic phenylketonuria and mild hyperphenyl-alaninaemia: experience in a paediatric population. Dev Med Child Neurol. 2005;47(7):443\u20138.","journal-title":"Dev Med Child Neurol"},{"issue":"1\u20132","key":"3840_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2007.05.006","volume":"92","author":"SE Waisbren","year":"2007","unstructured":"Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: A systematic literature review and meta-analysis. Mol Genet Metab. 2007;92(1\u20132):63\u201370.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"3840_CR48","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10545-012-9564-0","volume":"36","author":"CJ Fonnesbeck","year":"2013","unstructured":"Fonnesbeck CJ, McPheeters ML, Krishnaswami S, Lindegren ML, Reimschisel T. Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis. J Inherit Metab Dis. 2013;36(5):757\u201366.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3840_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1467-8721.2009.01604.x","volume":"18","author":"KF Widaman","year":"2009","unstructured":"Widaman KF. Phenylketonuria in children and mothers. Curr Dir Psychol Sci. 2009;18(1):48\u201352.","journal-title":"Curr Dir Psychol Sci"},{"key":"3840_CR50","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.ymgme.2013.10.006","volume":"110","author":"B Pode-Shakked","year":"2013","unstructured":"Pode-Shakked B, Shemer-Meiri L, Harmelin A, Stettner N, Brenner O, Abraham S, et al. Man made disease: clinical manifestations of low phenylalanine levels in an inadequately treated phenylketonuria patient and mouse study. Mol Genet Metab. 2013;110:S66\u201370.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3840_CR51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ymgme.2011.03.019","volume":"103","author":"Y Sanayama","year":"2011","unstructured":"Sanayama Y, Nagasaka H, Takayanagi M, Ohura T, Sakamoto O, Ito T, et al. Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria. Mol Genet Metab. 2011;103(3):220\u20135.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3840_CR52","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1148\/radiol.2362040611","volume":"236","author":"K Kono","year":"2005","unstructured":"Kono K, Okano Y, Nakayama K, Hase Y, Minamikawa S, Ozawa N, et al. Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter. Radiology. 2005;236(2):630\u20136.","journal-title":"Radiology"},{"issue":"12","key":"3840_CR53","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00234-009-0574-z","volume":"51","author":"R Manara","year":"2009","unstructured":"Manara R, Burlina AP, Citton V, Ermani M, Vespignani F, Carollo C, et al. Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria. Neuroradiology. 2009;51(12):803\u201312.","journal-title":"Neuroradiology"},{"issue":"1","key":"3840_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/archpedi.1991.02160010037012","volume":"145","author":"CG Azen","year":"1991","unstructured":"Azen CG. Intellectual development in 12-Year-Old children treated for phenylketonuria. Arch Pediatr Adolesc Med. 1991;145(1):35.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"3840_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/jpepsy\/24.3.281","volume":"24","author":"J Sullivan","year":"1999","unstructured":"Sullivan J. Review: emotional and behavioral functioning in phenylketonuria. J Pediatr Psychol. 1999;24(3):281\u201399.","journal-title":"J Pediatr Psychol"},{"issue":"1","key":"3840_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2012.11.003","volume":"108","author":"BK Burton","year":"2013","unstructured":"Burton BK, Leviton L, Vespa H, Coon H, Longo N, Lundy BD, et al. A diversified approach for PKU treatment: routine screening yields high incidence of psychiatric distress in phenylketonuria clinics. Mol Genet Metab. 2013;108(1):8\u201312.","journal-title":"Mol Genet Metab"},{"key":"3840_CR57","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.ymgme.2009.10.182","volume":"99","author":"VL Brumm","year":"2010","unstructured":"Brumm VL, Bilder D, Waisbren SE. Psychiatric symptoms and disorders in phenylketonuria\u2606. Mol Genet Metab. 2010;99:S59\u201363.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"3840_CR58","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/jhn.13015","volume":"35","author":"SJ Firman","year":"2022","unstructured":"Firman SJ, Ramachandran R, Whelan K. Knowledge, perceptions and behaviours regarding dietary management of adults living with phenylketonuria. J Hum Nutr Dietetics. 2022;35(6):1016\u201329.","journal-title":"J Hum Nutr Dietetics"},{"issue":"7","key":"3840_CR59","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1002\/ajmg.a.62195","volume":"185","author":"KI Teruya","year":"2021","unstructured":"Teruya KI, Remor E, Schwartz IVD. Factors that increase risk for poor adherence to phenylketonuria treatment in Brazilian patients. Am J Med Genet A. 2021;185(7):1991\u20132002.","journal-title":"Am J Med Genet A"},{"issue":"2\u20133","key":"3840_CR60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2010.05.017","volume":"101","author":"GM Enns","year":"2010","unstructured":"Enns GM, Koch R, Brumm V, Blakely E, Suter R, Jurecki E. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab. 2010;101(2\u20133):99\u2013109.","journal-title":"Mol Genet Metab"},{"key":"3840_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-3-030-67727-5_20","volume-title":"Physician\u2019s guide to the diagnosis, treatment, and Follow-Up of inherited metabolic diseases","author":"A Burlina","year":"2022","unstructured":"Burlina A, van Spronsen FJ, Blau N. Disorders of phenylalanine and tetrahydrobiopterin metabolism. Physician\u2019s guide to the diagnosis, treatment, and Follow-Up of inherited metabolic diseases. Cham: Springer International Publishing; 2022. pp. 331\u201351."},{"issue":"3","key":"3840_CR62","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.neubiorev.2008.11.001","volume":"33","author":"J Albrecht","year":"2009","unstructured":"Albrecht J, Garbade SF, Burgard P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: A meta-analysis. Neurosci Biobehav Rev. 2009;33(3):414\u201321.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"3840_CR63","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10545-005-0014-0","volume":"28","author":"MR Crone","year":"2005","unstructured":"Crone MR, van Spronsen FJ, Oudshoorn K, Bekhof J, van Rijn G, Verkerk PH. Behavioural factors related to metabolic control in patients with phenylketonuria. J Inherit Metab Dis. 2005;28(5):627\u201337.","journal-title":"J Inherit Metab Dis"},{"key":"3840_CR64","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.ymgme.2009.10.009","volume":"99","author":"D Janzen","year":"2010","unstructured":"Janzen D, Nguyen M. Beyond executive function: Non-executive cognitive abilities in individuals with PKU\u2606. Mol Genet Metab. 2010;99:S47\u201351.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3840_CR65","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10545-011-9284-x","volume":"34","author":"U M\u00fctze","year":"2011","unstructured":"M\u00fctze U, Roth A, Weigel JFW, Beblo S, Baerwald CG, B\u00fchrdel P, et al. Transition of young adults with phenylketonuria from pediatric to adult care. J Inherit Metab Dis. 2011;34(3):701\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"3840_CR66","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/abio.370040210","volume":"4","author":"M Prause","year":"1984","unstructured":"Prause M, Schulz H-J, Wagler D. Rechnergest\u00fctzte f\u00fchrung von fermentationsprozessen, teil 2. Acta Biotechnol. 1984;4(2):143\u201351.","journal-title":"Acta Biotechnol"},{"issue":"1","key":"3840_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-015-0378-7","volume":"10","author":"MJ Pena","year":"2015","unstructured":"Pena MJ, Almeida MF, van Dam E, Ahring K, B\u00e9langer-Quintana A, Dokoupil K, et al. Special low protein foods for phenylketonuria: availability in Europe and an examination of their nutritional profile. Orphanet J Rare Dis. 2015;10(1):162.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3840_CR68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13023-023-02621-9","volume":"18","author":"O Yilmaz","year":"2023","unstructured":"Yilmaz O, Cochrane B, Wildgoose J, Pinto A, Evans S, Daly A, et al. Phenylalanine free infant formula in the dietary management of phenylketonuria. Orphanet J Rare Dis. 2023;18(1):16.","journal-title":"Orphanet J Rare Dis"},{"key":"3840_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pedn.2017.10.009","volume":"38","author":"E Kose","year":"2018","unstructured":"Kose E, Aksoy B, Kuyum P, Tuncer N, Arslan N, Ozturk Y. The effects of breastfeeding in infants with phenylketonuria. J Pediatr Nurs. 2018;38:27\u201332.","journal-title":"J Pediatr Nurs"},{"issue":"1","key":"3840_CR70","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.pedn.2014.05.003","volume":"30","author":"SA Banta-Wright","year":"2015","unstructured":"Banta-Wright SA, Kodadek SM, Steiner RD, Houck GM. Challenges to breastfeeding infants with phenylketonuria. J Pediatr Nurs. 2015;30(1):219\u201326.","journal-title":"J Pediatr Nurs"},{"issue":"S1","key":"3840_CR71","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1007\/PL00014228","volume":"155","author":"F Cockburn","year":"1996","unstructured":"Cockburn F, Clark BJ. Recommendations for protein and amino acid intake in phenylketonuric patients. Eur J Pediatr. 1996;155(S1):S125\u20139.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"3840_CR72","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.nut.2007.03.009","volume":"23","author":"M van Rijn","year":"2007","unstructured":"van Rijn M, Hoeksma M, Sauer P, Szczerbak B, Gross M, Reijngoud DJ, et al. Protein metabolism in adult patients with phenylketonuria. Nutrition. 2007;23(6):445\u201353.","journal-title":"Nutrition"},{"issue":"1\u20132","key":"3840_CR73","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ymgme.2017.07.007","volume":"122","author":"M Evans","year":"2017","unstructured":"Evans M, Truby H, Boneh A. The relationship between dietary intake, growth and body composition in phenylketonuria. Mol Genet Metab. 2017;122(1\u20132):36\u201342.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3840_CR74","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jped.2021.04.009","volume":"98","author":"AM Silveira","year":"2022","unstructured":"Silveira AM, Lima PL, Alves MRA, Soares RDL, Kanufre V, de Rodrigues C. Overweight\/obesity in adolescents with phenylketonuria: protective and predisposing factors. J Pediatr (Rio J). 2022;98(1):104\u201310.","journal-title":"J Pediatr (Rio J)"},{"issue":"10","key":"3840_CR75","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.3390\/nu13103443","volume":"13","author":"C Rodrigues","year":"2021","unstructured":"Rodrigues C, Pinto A, Faria A, Teixeira D, van Wegberg AMJ, Ahring K, et al. Is the Phenylalanine-Restricted diet a risk factor for overweight or obesity in patients with phenylketonuria (PKU)? A systematic review and Meta-Analysis. Nutrients. 2021;13(10):3443.","journal-title":"Nutrients"},{"issue":"1\u20132","key":"3840_CR76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymgme.2012.07.006","volume":"107","author":"LC Burrage","year":"2012","unstructured":"Burrage LC, McConnell J, Haesler R, O\u2019Riordan MA, Sutton VR, Kerr DS, et al. High prevalence of overweight and obesity in females with phenylketonuria. Mol Genet Metab. 2012;107(1\u20132):43\u20138.","journal-title":"Mol Genet Metab"},{"key":"3840_CR77","first-page":"100599","volume":"23","author":"M Sailer","year":"2020","unstructured":"Sailer M, Elizondo G, Martin J, Harding CO, Gillingham MB. Nutrient intake, body composition, and blood phenylalanine control in children with phenylketonuria compared to healthy controls. Mol Genet Metab Rep. 2020;23:100599.","journal-title":"Mol Genet Metab Rep"},{"key":"3840_CR78","doi-asserted-by":"crossref","unstructured":"Nogueira ZD, Boa-Sorte N, Leite ME, de Toralles Q, Amorim MBP, T. Metabolic control and body composition of children and adolescents with phenylketonuria. Revista Paulista De Pediatria. 2021;39.","DOI":"10.1590\/1984-0462\/2021\/39\/2020095"},{"issue":"6","key":"3840_CR79","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10545-010-9043-4","volume":"33","author":"F Feillet","year":"2010","unstructured":"Feillet F, Agostoni C. Nutritional issues in treating phenylketonuria. J Inherit Metab Dis. 2010;33(6):659\u201364.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3840_CR80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10545-008-0966-y","volume":"32","author":"FJ van Spronsen","year":"2009","unstructured":"van Spronsen FJ, Ahring KK, Gizewska M. PKU\u2014What is daily practice in various centres in europe?? J Inherit Metab Dis. 2009;32(1):58\u201364.","journal-title":"J Inherit Metab Dis"},{"key":"3840_CR81","doi-asserted-by":"crossref","unstructured":"Rocha JC, MacDonald A. Dietary intervention in the management of phenylketonuria: current perspectives. Pediatr Health Med Ther 2016;7:155\u201363.","DOI":"10.2147\/PHMT.S49329"},{"issue":"6","key":"3840_CR82","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.3390\/nu12061893","volume":"12","author":"G Wood","year":"2020","unstructured":"Wood G, Evans S, Pointon-Bell K, Rocha JC, MacDonald A. Special low protein foods in the UK: an examination of their macronutrient composition in comparison to regular foods. Nutrients. 2020;12(6):1893.","journal-title":"Nutrients"},{"key":"3840_CR83","doi-asserted-by":"crossref","unstructured":"Arslan E, Gokcay GF. Special low protein foods for phenylketonuria in turkey: an examination of their nutritional composition compared to regular food. Nutr Health. 2023;026010602211465.","DOI":"10.1177\/02601060221146580"},{"issue":"5","key":"3840_CR84","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/ejcn.2011.205","volume":"66","author":"C Rohde","year":"2012","unstructured":"Rohde C, M\u00fctze U, Weigel JFW, Ceglarek U, Thiery J, Kiess W, et al. Unrestricted consumption of fruits and vegetables in phenylketonuria: no major impact on metabolic control. Eur J Clin Nutr. 2012;66(5):633\u20138.","journal-title":"Eur J Clin Nutr"},{"issue":"2","key":"3840_CR85","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/nu13020707","volume":"13","author":"E Newbould","year":"2021","unstructured":"Newbould E, Pinto A, Evans S, Ford S, O\u2019Driscoll M, Ashmore C, et al. Accidental consumption of aspartame in phenylketonuria: patient experiences. Nutrients. 2021;13(2):707.","journal-title":"Nutrients"},{"issue":"1","key":"3840_CR86","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13023-023-02770-x","volume":"18","author":"V Maler","year":"2023","unstructured":"Maler V, Goetz V, Tardieu M, Khalil A, El, Alili JM, Meunier P, et al. Aspartame and phenylketonuria: an analysis of the daily phenylalanine intake of aspartame-containing drugs marketed in France. Orphanet J Rare Dis. 2023;18(1):142.","journal-title":"Orphanet J Rare Dis"},{"key":"3840_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/6859820","volume":"2017","author":"BM Stroup","year":"2017","unstructured":"Stroup BM, Ney DM, Murali SG, Rohr F, Gleason ST, van Calcar SC, et al. Metabolomic insights into the nutritional status of adults and adolescents with phenylketonuria consuming a Low-Phenylalanine diet in combination with amino acid and glycomacropeptide medical foods. J Nutr Metab. 2017;2017:1\u201317.","journal-title":"J Nutr Metab"},{"issue":"2","key":"3840_CR88","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/ajcn\/73.2.153","volume":"73","author":"FJ van Spronsen","year":"2001","unstructured":"van Spronsen FJ, van Rijn M, Bekhof J, Koch R, Smit PG. Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets. Am J Clin Nutr. 2001;73(2):153\u20137.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"3840_CR89","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s10545-006-0395-8","volume":"29","author":"R Matalon","year":"2006","unstructured":"Matalon R, Michals-Matalon K, Bhatia G, Grechanina E, Novikov P, McDonald JD, et al. Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis. 2006;29(6):732\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"3840_CR90","doi-asserted-by":"publisher","first-page":"e0143833","DOI":"10.1371\/journal.pone.0143833","volume":"10","author":"D van Vliet","year":"2015","unstructured":"van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MHJR, de Blaauw P, Kema IP, et al. Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice. PLoS ONE. 2015;10(12):e0143833.","journal-title":"PLoS ONE"},{"issue":"4","key":"3840_CR91","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/nu12041092","volume":"12","author":"I Scala","year":"2020","unstructured":"Scala I, Riccio MP, Marino M, Bravaccio C, Parenti G, Strisciuglio P. Large neutral amino acids (LNAAs) supplementation improves neuropsychological performances in adult patients with phenylketonuria. Nutrients. 2020;12(4):1092.","journal-title":"Nutrients"},{"issue":"4","key":"3840_CR92","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/ijms23042227","volume":"23","author":"N Giarratana","year":"2022","unstructured":"Giarratana N, Giardino L, Bighinati A, Reiner G, Rocha JC. In vivo metabolic responses to different formulations of amino acid mixtures for the treatment of phenylketonuria (PKU). Int J Mol Sci. 2022;23(4):2227.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3840_CR93","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3390\/nu12072078","volume":"12","author":"AP Burlina","year":"2020","unstructured":"Burlina AP, Cazzorla C, Massa P, Loro C, Gueraldi D, Burlina AB. The impact of a Slow-Release large neutral amino acids supplement on treatment adherence in adult patients with phenylketonuria. Nutrients. 2020;12(7):2078.","journal-title":"Nutrients"},{"issue":"11","key":"3840_CR94","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/nu13114012","volume":"13","author":"I Scala","year":"2021","unstructured":"Scala I, Concolino D, Nastasi A, Esposito G, Crisci D, Sestito S, et al. Beneficial effects of Slow-Release large neutral amino acids after a phenylalanine oral load in patients with phenylketonuria. Nutrients. 2021;13(11):4012.","journal-title":"Nutrients"},{"issue":"5","key":"3840_CR95","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10545-012-9548-0","volume":"36","author":"JB Hennermann","year":"2013","unstructured":"Hennermann JB, Roloff S, Gellermann J, Vollmer I, Windt E, Vetter B, et al. Chronic kidney disease in adolescent and adult patients with phenylketonuria. J Inherit Metab Dis. 2013;36(5):747\u201356.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3840_CR96","doi-asserted-by":"publisher","first-page":"S1693","DOI":"10.1093\/jn\/137.6.1693S","volume":"137","author":"GK Grimble","year":"2007","unstructured":"Grimble GK. Adverse Gastrointestinal effects of arginine and related amino acids. J Nutr. 2007;137(6):S1693\u2013701.","journal-title":"J Nutr"},{"issue":"3","key":"3840_CR97","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-277X.1997.00050.x","volume":"10","author":"A MacDonald","year":"1997","unstructured":"MacDonald A, Harris G, Rylance G, Asplin D, Booth IW. Abnormal feeding behaviours in phenylketonuria. J Hum Nutr Dietetics. 1997;10(3):163\u201370.","journal-title":"J Hum Nutr Dietetics"},{"key":"3840_CR98","unstructured":"Genetic Metabolic Dietitians International, SouthEast Regional Genetics Network. PKU Nutrition Management Guidelines [Internet]. 2022 [cited 2024 Jan 4]. Available from: https:\/\/managementguidelines.net\/guidelines.php\/136\/PKU%20Nutrition%20Guidelines\/Version%202.5"},{"issue":"4","key":"3840_CR99","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1023\/A:1025186217369","volume":"26","author":"A MacDonald","year":"2003","unstructured":"MacDonald A, Rylance G, Davies P, Asplin D, Hall SK, Booth IW. Administration of protein substitute and quality of control in phenylketonuria: A randomized study. J Inherit Metab Dis. 2003;26(4):319\u201326.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"3840_CR100","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10545-007-0556-4","volume":"30","author":"R Matalon","year":"2007","unstructured":"Matalon R, Michals-Matalon K, Bhatia G, Burlina AB, Burlina AP, Braga C, et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis. 2007;30(2):153\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3840_CR101","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000363391","volume":"65","author":"S Evans","year":"2014","unstructured":"Evans S, Daly A, MacDonald J, Preece MA, Santra S, Vijay S, et al. The micronutrient status of patients with phenylketonuria on dietary treatment: an ongoing challenge. Ann Nutr Metab. 2014;65(1):42\u20138.","journal-title":"Ann Nutr Metab"},{"issue":"1","key":"3840_CR102","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/ejcn.2013.218","volume":"68","author":"C Rohde","year":"2014","unstructured":"Rohde C, von Teeffelen-Heithoff A, Thiele AG, Arelin M, M\u00fctze U, Kiener C, et al. PKU patients on a relaxed diet May be at risk for micronutrient deficiencies. Eur J Clin Nutr. 2014;68(1):119\u201324.","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"3840_CR103","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13023-015-0232-y","volume":"10","author":"S Demirdas","year":"2015","unstructured":"Demirdas S, Coakley KE, Bisschop PH, Hollak CEM, Bosch AM, Singh RH. Bone health in phenylketonuria: a systematic review and meta-analysis. Orphanet J Rare Dis. 2015;10(1):17.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3840_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2017.03.002","volume":"121","author":"DA Bilder","year":"2017","unstructured":"Bilder DA, Kobori JA, Cohen-Pfeffer JL, Johnson EM, Jurecki ER, Grant ML. Neuropsychiatric comorbidities in adults with phenylketonuria: A retrospective cohort study. Mol Genet Metab. 2017;121(1):1\u20138.","journal-title":"Mol Genet Metab"},{"key":"3840_CR105","first-page":"10","volume":"14","author":"S Evans","year":"2018","unstructured":"Evans S, Daly A, Chahal S, Ashmore C, MacDonald J, MacDonald A. The influence of parental food preference and neophobia on children with phenylketonuria (PKU). Mol Genet Metab Rep. 2018;14:10\u20134.","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"3840_CR106","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jhn.12346","volume":"29","author":"S Evans","year":"2016","unstructured":"Evans S, Daly A, Chahal S, MacDonald J, MacDonald A. Food acceptance and neophobia in children with phenylketonuria: a prospective controlled study. J Hum Nutr Dietetics. 2016;29(4):427\u201333.","journal-title":"J Hum Nutr Dietetics"},{"issue":"4","key":"3840_CR107","doi-asserted-by":"publisher","first-page":"108","DOI":"10.14740\/jem581","volume":"9","author":"T Tonon","year":"2019","unstructured":"Tonon T, Martinez C, Poloni S, Nalin T, MacDonald A, Schwartz IVD. Food neophobia in patients with phenylketonuria. J Endocrinol Metab. 2019;9(4):108\u201312.","journal-title":"J Endocrinol Metab"},{"issue":"5","key":"3840_CR108","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/bcp.13886","volume":"85","author":"J Qu","year":"2019","unstructured":"Qu J, Yang T, Wang E, Li M, Chen C, Ma L, et al. Efficacy and safety of Sapropterin dihydrochloride in patients with phenylketonuria: A meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2019;85(5):893\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3840_CR109","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","volume":"30","author":"BK Burton","year":"2007","unstructured":"Burton BK, Grange DK, Milanowski A, Vockley G, Feillet F, Crombez EA, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral Sapropterin dihydrochloride (6 R -tetrahydrobiopterin): a phase II, multicentre, open\u2010label, screening study. J Inherit Metab Dis. 2007;30(5):700\u20137.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"3840_CR110","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1096-7192(02)00229-9","volume":"78","author":"LJM Spaapen","year":"2003","unstructured":"Spaapen LJM, Estela Rubio-Gozalbo M. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, state of the Art. Mol Genet Metab. 2003;78(2):93\u20139.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3840_CR111","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/humu.20637","volume":"29","author":"MR Zurfl\u00fch","year":"2008","unstructured":"Zurfl\u00fch MR, Zschocke J, Lindner M, Feillet F, Chery C, Burlina A, et al. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum Mutat. 2008;29(1):167\u201375.","journal-title":"Hum Mutat"},{"issue":"3","key":"3840_CR112","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ymgme.2010.03.022","volume":"100","author":"HJ Vernon","year":"2010","unstructured":"Vernon HJ, Koerner CB, Johnson MR, Bergner A, Hamosh A. Introduction of Sapropterin dihydrochloride as standard of care in patients with phenylketonuria. Mol Genet Metab. 2010;100(3):229\u201333.","journal-title":"Mol Genet Metab"},{"key":"3840_CR113","unstructured":"Blau N, BIOPKUdb. Database of Patients and Genotypes Causing HPA\/PKU incl. BH4-Responsive Phenotype [Internet]. 2023 [cited 2024 Feb 21]. Available from: http:\/\/www.biopku.org\/home\/biopku.asp"},{"issue":"6","key":"3840_CR114","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jpeds.2014.08.003","volume":"165","author":"H Shintaku","year":"2014","unstructured":"Shintaku H, Ohura T. Sapropterin is safe and effective in patients less than 4-Years-Old with BH4-Responsive phenylalanine hydroxylase deficiency. J Pediatr. 2014;165(6):1241\u20134.","journal-title":"J Pediatr"},{"issue":"9586","key":"3840_CR115","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","volume":"370","author":"HL Levy","year":"2007","unstructured":"Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, et al. Efficacy of Sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007;370(9586):504\u201310.","journal-title":"Lancet"},{"issue":"4","key":"3840_CR116","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ymgme.2011.03.020","volume":"103","author":"BK Burton","year":"2011","unstructured":"Burton BK, Nowacka M, Hennermann JB, Lipson M, Grange DK, Chakrapani A, et al. Safety of extended treatment with Sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study. Mol Genet Metab. 2011;103(4):315\u201322.","journal-title":"Mol Genet Metab"},{"key":"3840_CR117","unstructured":"U.S, Food. & Drug Administration. Drug Approval Package: PALYNZIQ (pegvaliase-pqpz) [Internet]. 2018 [cited 2023 Dec 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761079Orig1s000TOC.cfm"},{"key":"3840_CR118","unstructured":"European Medicines Agency. Palynziq [Internet]. 2019 [cited 2023 Dec 7]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/palynziq#authorisation-details-section"},{"issue":"1","key":"3840_CR119","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","volume":"124","author":"J Thomas","year":"2018","unstructured":"Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, et al. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018;124(1):27\u201338.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3840_CR120","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/03007995.2018.1528215","volume":"35","author":"KC Mahan","year":"2019","unstructured":"Mahan KC, Gandhi MA, Anand S. Pegvaliase: a novel treatment option for adults with phenylketonuria. Curr Med Res Opin. 2019;35(4):647\u201351.","journal-title":"Curr Med Res Opin"},{"issue":"1\u20132","key":"3840_CR121","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ymgme.2019.07.018","volume":"128","author":"R Zori","year":"2019","unstructured":"Zori R, Ahring K, Burton B, Pastores GM, Rutsch F, Jha A, et al. Long-term comparative effectiveness of Pegvaliase versus standard of care comparators in adults with phenylketonuria. Mol Genet Metab. 2019;128(1\u20132):92\u2013101.","journal-title":"Mol Genet Metab"},{"key":"3840_CR122","doi-asserted-by":"publisher","unstructured":"Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder DA et al. Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. GENETICS in MEDICINE [Internet]. 2019;21(8):1851\u201367. Available from: https:\/\/doi.org\/10.1038\/s41436-018-0403-z","DOI":"10.1038\/s41436-018-0403-z"},{"key":"3840_CR123","first-page":"100571","volume":"23","author":"J Beazer","year":"2020","unstructured":"Beazer J, Breck J, Eggerding C, Gordon P, Hacker S, Thompson A. Strategies to engage lost to follow-up patients with phenylketonuria in the united states: best practice recommendations. Mol Genet Metab Rep. 2020;23:100571.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"3840_CR124","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1186\/1471-2458-14-1243","volume":"14","author":"C Cazzorla","year":"2014","unstructured":"Cazzorla C, Cegolon L, Burlina AP, Celato A, Massa P, Giordano L, et al. Quality of life (QoL) assessment in a cohort of patients with phenylketonuria. BMC Public Health. 2014;14(1):1243.","journal-title":"BMC Public Health"},{"issue":"S2","key":"3840_CR125","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10545-008-0978-7","volume":"31","author":"M Bik-Multanowski","year":"2008","unstructured":"Bik-Multanowski M, Didycz B, Mozrzymas R, Nowacka M, Kaluzny L, Cichy W, et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis. 2008;31(S2):415\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"3840_CR126","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","volume":"120","author":"ER Jurecki","year":"2017","unstructured":"Jurecki ER, Cederbaum S, Kopesky J, Perry K, Rohr F, Sanchez-Valle A, et al. Adherence to clinic recommendations among patients with phenylketonuria in the united States. Mol Genet Metab. 2017;120(3):190\u20137.","journal-title":"Mol Genet Metab"},{"issue":"2\u20133","key":"3840_CR127","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ymgme.2010.06.006","volume":"101","author":"BK Burton","year":"2010","unstructured":"Burton BK, Leviton L. Reaching out to the lost generation of adults with early-treated phenylketonuria (PKU). Mol Genet Metab. 2010;101(2\u20133):146\u20138.","journal-title":"Mol Genet Metab"},{"key":"3840_CR128","first-page":"101099","volume":"40","author":"S Sacharow","year":"2024","unstructured":"Sacharow S, Zhu E, Hollander S. The challenge of adults with phenylketonuria who have been lost to care; a single center\u2019s attempt to reach those diagnosed with PKU over 60 years of newborn screening. Mol Genet Metab Rep. 2024;40:101099.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"3840_CR129","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0022-3476(00)90050-7","volume":"136","author":"B Rouse","year":"2000","unstructured":"Rouse B, Matalon R, Koch R, Azen C, Levy H, Hanley W, et al. Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes. J Pediatr. 2000;136(1):57\u201361.","journal-title":"J Pediatr"},{"issue":"1","key":"3840_CR130","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s13023-021-02108-5","volume":"16","author":"C Rohde","year":"2021","unstructured":"Rohde C, Thiele AG, Baerwald C, Ascherl RG, Lier D, Och U, et al. Preventing maternal phenylketonuria (PKU) syndrome: important factors to achieve good metabolic control throughout pregnancy. Orphanet J Rare Dis. 2021;16(1):477.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3840_CR131","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1023\/B:BOLI.0000045758.86492.54","volume":"27","author":"WB Hanley","year":"2004","unstructured":"Hanley WB, Azen C, Koch R, Michals-Matalon K, Matalon R, Rouse B, et al. Maternal phenylketonuria collaborative study (MPKUCS)\u2014The outliers. J Inherit Metab Dis. 2004;27(6):711\u201323.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3840_CR132","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s10545-012-9491-0","volume":"35","author":"R Teissier","year":"2012","unstructured":"Teissier R, Nowak E, Assoun M, Mention K, Cano A, Fouilhoux A, et al. Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation. J Inherit Metab Dis. 2012;35(6):993\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3840_CR133","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.numecd.2020.02.003","volume":"30","author":"MT Caletti","year":"2020","unstructured":"Caletti MT, Bettocchi I, Baronio F, Brodosi L, Cataldi S, Petroni ML, et al. Maternal PKU: defining phenylalanine tolerance and its variation during pregnancy, according to genetic background. Nutr Metabolism Cardiovasc Dis. 2020;30(6):977\u201383.","journal-title":"Nutr Metabolism Cardiovasc Dis"},{"issue":"9","key":"3840_CR134","first-page":"100358","volume":"25","author":"AD Adams","year":"2023","unstructured":"Adams AD, Fiesco-Roa M\u00d3, Wong L, Jenkins GP, Malinowski J, Demarest OM, et al. Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American college of medical genetics and genomics (ACMG). Genet Sci. 2023;25(9):100358.","journal-title":"Genet Sci"},{"issue":"2","key":"3840_CR135","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s10545-007-0436-y","volume":"30","author":"F Maillot","year":"2007","unstructured":"Maillot F, Cook P, Lilburn M, Lee PJ. A practical approach to maternal phenylketonuria management. J Inherit Metab Dis. 2007;30(2):198\u2013201.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3840_CR136","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/jimd.12544","volume":"45","author":"K Grohmann-Held","year":"2022","unstructured":"Grohmann-Held K, Burgard P, Baerwald CGO, Beblo S, vom Dahl S, Das A, et al. Impact of pregnancy planning and preconceptual dietary training on metabolic control and offspring\u2019s outcome in phenylketonuria. J Inherit Metab Dis. 2022;45(6):1070\u201381.","journal-title":"J Inherit Metab Dis"},{"key":"3840_CR137","doi-asserted-by":"crossref","unstructured":"Feillet F, Ficicioglu C, Lagler FB, Longo N, Muntau AC, Burlina A et al. Efficacy and safety of sapropterin before and during pregnancy: Final analysis of the Kuvan\u00ae Adult Maternal Paediatric European Registry (<\u2009scp\u2009>\u2009KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (<\u2009scp\u2009>\u2009PKUDOS) <\u2009scp\u2009>\u2009PKU-MOMs\u2009sub\u2010registries. J Inherit Metab Dis. 2024.","DOI":"10.1002\/jimd.12724"},{"issue":"4","key":"3840_CR138","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s10545-009-1132-x","volume":"32","author":"JC Rocha","year":"2009","unstructured":"Rocha JC, Martel F. Large neutral amino acids supplementation in phenylketonuric patients. J Inherit Metab Dis. 2009;32(4):472\u201380.","journal-title":"J Inherit Metab Dis"},{"issue":"3\u20134","key":"3840_CR139","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000479746","volume":"71","author":"M Hochuli","year":"2017","unstructured":"Hochuli M, Bollhalder S, Thierer C, Refardt J, Gerber P, Baumgartner MR. Effects of inadequate amino acid mixture intake on nutrient supply of adult patients with phenylketonuria. Ann Nutr Metab. 2017;71(3\u20134):129\u201335.","journal-title":"Ann Nutr Metab"},{"issue":"5","key":"3840_CR140","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/nu14051021","volume":"14","author":"MI Gama","year":"2022","unstructured":"Gama MI, Pinto A, Daly A, Rocha JC, MacDonald A. The impact of the quality of nutrition and lifestyle in the reproductive years of women with PKU on the Long-Term health of their children. Nutrients. 2022;14(5):1021.","journal-title":"Nutrients"},{"issue":"8","key":"3840_CR141","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/1028415X.2018.1538196","volume":"23","author":"PD Manta-Vogli","year":"2020","unstructured":"Manta-Vogli PD, Dotsikas Y, Loukas YL, Schulpis KH. The phenylketonuria patient: A recent dietetic therapeutic approach. Nutr Neurosci. 2020;23(8):628\u201339.","journal-title":"Nutr Neurosci"},{"issue":"2","key":"3840_CR142","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s13679-024-00554-3","volume":"13","author":"C Panzeri","year":"2024","unstructured":"Panzeri C, Pecoraro L, Dianin A, Sboarina A, Arnone OC, Piacentini G, et al. Potential micronutrient deficiencies in the first 1000 days of life: the pediatrician on the side of the weakest. Curr Obes Rep. 2024;13(2):338\u201351.","journal-title":"Curr Obes Rep"},{"issue":"Supplement4","key":"3840_CR143","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1542\/peds.112.S4.1534","volume":"112","author":"KM Matalon","year":"2003","unstructured":"Matalon KM, Acosta PB, Azen C. Role of nutrition in pregnancy with phenylketonuria and birth defects. Pediatrics. 2003;112(Supplement4):1534\u20136.","journal-title":"Pediatrics"},{"issue":"1","key":"3840_CR144","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000365767","volume":"65","author":"B Koletzko","year":"2014","unstructured":"Koletzko B, Boey CCM, Campoy C, Carlson SE, Chang N, Guillermo-Tuazon MA, et al. Current information and Asian perspectives on Long-Chain polyunsaturated fatty acids in pregnancy, lactation, and infancy: systematic review and practice recommendations from an early nutrition academy workshop. Ann Nutr Metab. 2014;65(1):49\u201380.","journal-title":"Ann Nutr Metab"},{"issue":"3","key":"3840_CR145","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF00710414","volume":"18","author":"M Giovannini","year":"1995","unstructured":"Giovannini M, Biasucci G, Agostoni C, Luotti D, Riva E. Lipid status and fatty acid metabolism in phenylketonuria. J Inherit Metab Dis. 1995;18(3):265\u201372.","journal-title":"J Inherit Metab Dis"},{"issue":"S1","key":"3840_CR146","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1007\/PL00014230","volume":"155","author":"M Giovannini","year":"1996","unstructured":"Giovannini M, Agostoni C, Biasucci G, Rottoli A, Luotti D, Trojan S, et al. Fatty acid metabolism in phenylketonuria. Eur J Pediatr. 1996;155(S1):S132\u20135.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"3840_CR147","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ymgme.2013.03.006","volume":"109","author":"JJ Jans","year":"2013","unstructured":"Jans JJ, de Sain-van der Velden MGM, van Hasselt PM, van den Hurk DTAM, Vaz FM, Visser G, et al. Supplementation with a powdered blend of PUFAs normalizes DHA and AA levels in patients with PKU. Mol Genet Metab. 2013;109(2):121\u20134.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"3840_CR148","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00431-004-1482-1","volume":"163","author":"F Feillet","year":"2004","unstructured":"Feillet F, Abadie V, Berthelot J, Maurin N, Ogier H, Vidailhet M, et al. Maternal phenylketonuria: the French survey. Eur J Pediatr. 2004;163(9):540\u20136.","journal-title":"Eur J Pediatr"},{"issue":"s1","key":"3840_CR149","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1365-3016.2012.01308.x","volume":"26","author":"A Imdad","year":"2012","unstructured":"Imdad A, Bhutta ZA. Maternal nutrition and birth outcomes: effect of balanced Protein-Energy supplementation. Paediatr Perinat Epidemiol. 2012;26(s1):178\u201390.","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"4","key":"3840_CR150","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/ajcn\/73.4.792","volume":"73","author":"PB Acosta","year":"2001","unstructured":"Acosta PB, Matalon K, Castiglioni L, Rohr FJ, Wenz E, Austin V, et al. Intake of major nutrients by women in the maternal phenylketonuria (MPKU) study and effects on plasma phenylalanine concentrations. Am J Clin Nutr. 2001;73(4):792\u20136.","journal-title":"Am J Clin Nutr"},{"key":"3840_CR151","doi-asserted-by":"crossref","unstructured":"Hanson MA, Bardsley A, De-Regil LM, Moore SE, Oken E, Poston L et al. The international federation of gynecology and obstetrics (FIGO) recommendations on adolescent, preconception, and maternal nutrition: think nutrition first #. Int J Gynecol Obstet. 2015;131(S4).","DOI":"10.1016\/S0020-7292(15)30034-5"},{"issue":"8937","key":"3840_CR152","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S0140-6736(94)90404-9","volume":"344","author":"HL Levy","year":"1994","unstructured":"Levy HL, Waisbren SE, Lobbregt D, Allred E, Leviton A, Schuler A, et al. Maternal mild hyperphenylalaninaemia: an international survey of offspring outcome. Lancet. 1994;344(8937):1589\u201394.","journal-title":"Lancet"},{"issue":"1\u20132","key":"3840_CR153","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1006\/mgme.2000.3038","volume":"71","author":"R Koch","year":"2000","unstructured":"Koch R, Hanley W, Levy H, Matalon R, Rouse B, Trefz F, et al. Maternal phenylketonuria: an international study. Mol Genet Metab. 2000;71(1\u20132):233\u20139.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"3840_CR154","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/(SICI)1097-0223(199607)16:7<599::AID-PD915>3.0.CO;2-5","volume":"16","author":"HL LEVY","year":"1996","unstructured":"LEVY HL, LOBBREGT D, PLATT LD, BENACERRAF BR. FETAL ULTRASONOGRAPHY IN MATERNAL PKU. Prenat Diagn. 1996;16(7):599\u2013604.","journal-title":"Prenat Diagn"},{"issue":"5","key":"3840_CR155","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1203\/00006450-200105000-00005","volume":"49","author":"HL Levy","year":"2001","unstructured":"Levy HL, Guldberg P, G\u00fcttler F, Hanley WB, Matalon R, Rouse BM, et al. Congenital heart disease in maternal phenylketonuria: report from the maternal PKU collaborative study. Pediatr Res. 2001;49(5):636\u201342.","journal-title":"Pediatr Res"},{"key":"3840_CR156","doi-asserted-by":"crossref","unstructured":"Waisbren SE, Rohr F, Anastasoaie V, Brown M, Harris D, Ozonoff A et al. In. Maternal phenylketonuria: Long-term outcomes in offspring and Post-pregnancy maternal characteristics. 2014;23\u201333.","DOI":"10.1007\/8904_2014_365"},{"issue":"7","key":"3840_CR157","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/bfm.2020.0109","volume":"15","author":"PO Anderson","year":"2020","unstructured":"Anderson PO. Drug therapy of genetic diseases during breastfeeding. Breastfeed Med. 2020;15(7):426\u20138.","journal-title":"Breastfeed Med"},{"issue":"9","key":"3840_CR158","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1177\/000992289703600908","volume":"36","author":"C Fox-Bacon","year":"1997","unstructured":"Fox-Bacon C, McCamman S, Therou L, Moore W, Kipp DE. Maternal PKU and breastfeeding: case report of identical twin mothers. Clin Pediatr (Phila). 1997;36(9):539\u201342.","journal-title":"Clin Pediatr (Phila)"},{"issue":"2","key":"3840_CR159","first-page":"121","volume":"16","author":"RH Singh","year":"2014","unstructured":"Singh RH, Rohr F, Frazier D, Cunningham A, Mofidi S, Ogata B, et al. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Sci. 2014;16(2):121\u201331.","journal-title":"Genet Sci"},{"issue":"s2","key":"3840_CR160","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1740-8709.2010.00276.x","volume":"6","author":"V Hall Moran","year":"2010","unstructured":"Hall Moran V, Lowe N, Crossland N, Berti C, Cetin I, Hermoso M, et al. Nutritional requirements during lactation. Towards European alignment of reference values: the EURRECA network. Matern Child Nutr. 2010;6(s2):39\u201354.","journal-title":"Matern Child Nutr"},{"issue":"9","key":"3840_CR161","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","volume":"5","author":"FJ van Spronsen","year":"2017","unstructured":"van Spronsen FJ, van Wegberg AM, Ahring K, B\u00e9langer-Quintana A, Blau N, Bosch AM, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3840_CR162","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymgme.2021.01.001","volume":"132","author":"S Waisbren","year":"2021","unstructured":"Waisbren S, Burton BK, Feigenbaum A, Konczal LL, Lilienstein J, McCandless SE, et al. Long-term preservation of intellectual functioning in sapropterin-treated infants and young children with phenylketonuria: A seven-year analysis. Mol Genet Metab. 2021;132(2):119\u201327.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3840_CR163","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ymgme.2018.06.010","volume":"125","author":"R Zori","year":"2018","unstructured":"Zori R, Thomas JA, Shur N, Rizzo WB, Decker C, Rosen O, et al. Induction, titration, and maintenance dosing regimen in a phase 2 study of Pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Mol Genet Metab. 2018;125(3):217\u201327.","journal-title":"Mol Genet Metab"},{"key":"3840_CR164","doi-asserted-by":"publisher","first-page":"155116","DOI":"10.1016\/j.metabol.2021.155116","volume":"128","author":"D Bratkovic","year":"2022","unstructured":"Bratkovic D, Margvelashvili L, Tchan MC, Nisbet J, Smith N. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study. Metabolism. 2022;128:155116.","journal-title":"Metabolism"},{"issue":"4","key":"3840_CR165","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ymgme.2019.02.001","volume":"126","author":"N Smith","year":"2019","unstructured":"Smith N, Longo N, Levert K, Hyland K, Blau N. Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel Pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. Mol Genet Metab. 2019;126(4):406\u201312.","journal-title":"Mol Genet Metab"},{"key":"3840_CR166","doi-asserted-by":"crossref","unstructured":"Gao L, Kaushik D, Xia Y, Ingalls K, Milner S, Smith N et al. Relative oral bioavailability and food effects of two sepiapterin formulations in healthy participants. Clin Pharmacol Drug Dev. 2023.","DOI":"10.1002\/cpdd.1363"},{"key":"3840_CR167","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov [Internet]. [cited 2024 Feb 1]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/results?cond=PKU%26term=%26cntry=%26state=%26city=%26dist="},{"issue":"3","key":"3840_CR168","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40259-020-00415-0","volume":"34","author":"L Rossi","year":"2020","unstructured":"Rossi L, Pierig\u00e8 F, Aliano MP, Magnani M. Ongoing developments and clinical progress in Drug-Loaded red blood cell technologies. BioDrugs. 2020;34(3):265\u201372.","journal-title":"BioDrugs"},{"key":"3840_CR169","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2014.08.012","volume":"194","author":"L Rossi","year":"2014","unstructured":"Rossi L, Pierig\u00e8 F, Carducci C, Gabucci C, Pascucci T, Canonico B, et al. Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pahenu2 mice. J Controlled Release. 2014;194:37\u201344.","journal-title":"J Controlled Release"},{"issue":"3","key":"3840_CR170","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10571-010-9636-3","volume":"31","author":"A Sitta","year":"2011","unstructured":"Sitta A, Vanzin CS, Biancini GB, Manfredini V, de Oliveira AB, Wayhs CAY, et al. Evidence that l-Carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients. Cell Mol Neurobiol. 2011;31(3):429\u201336.","journal-title":"Cell Mol Neurobiol"},{"issue":"4","key":"3840_CR171","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/jnr.10307","volume":"69","author":"F Martinez-Cruz","year":"2002","unstructured":"Martinez-Cruz F, Pozo D, Osuna C, Espinar A, Marchante C, Guerrero JM. Oxidative stress induced by phenylketonuria in the rat: prevention by melatonin, vitamin E, and vitamin C. J Neurosci Res. 2002;69(4):550\u20138.","journal-title":"J Neurosci Res"},{"issue":"1","key":"3840_CR172","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jimd.12651","volume":"47","author":"M Martinez","year":"2024","unstructured":"Martinez M, Harding CO, Schwank G, Th\u00f6ny B. State-of\u2010the\u2010art 2023 on gene therapy for phenylketonuria. J Inherit Metab Dis. 2024;47(1):80\u201392.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"3840_CR173","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.gt.3302678","volume":"13","author":"CO Harding","year":"2006","unstructured":"Harding CO, Gillingham MB, Hamman K, Clark H, Goebel-Daghighi E, Bird A, et al. Complete correction of hyperphenylalaninemia following liver-directed, Recombinant AAV2\/8 vector-mediated gene therapy in murine phenylketonuria. Gene Ther. 2006;13(5):457\u201362.","journal-title":"Gene Ther"},{"key":"3840_CR174","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.omtm.2020.03.009","volume":"17","author":"SS Ahmed","year":"2020","unstructured":"Ahmed SS, Rubin H, Wang M, Faulkner D, Sengooba A, Dollive SN, et al. Sustained correction of a murine model of phenylketonuria following a single intravenous administration of AAVHSC15-PAH. Mol Ther Methods Clin Dev. 2020;17:568\u201380.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3840_CR175","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1126\/scitranslmed.abg3047","volume":"13","author":"A Vonada","year":"2021","unstructured":"Vonada A, Tiyaboonchai A, Nygaard S, Posey J, Peters AM, Winn SR, et al. Therapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes. Sci Transl Med. 2021;13:597.","journal-title":"Sci Transl Med"},{"key":"3840_CR176","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtn.2022.02.020","volume":"28","author":"CG Perez-Garcia","year":"2022","unstructured":"Perez-Garcia CG, Diaz-Trelles R, Vega JB, Bao Y, Sablad M, Limphong P, et al. Development of an mRNA replacement therapy for phenylketonuria. Mol Ther Nucleic Acids. 2022;28:87\u201398.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3840_CR177","doi-asserted-by":"crossref","unstructured":"Cacicedo ML, Weinl-Tenbruck C, Frank D, Limeres MJ, Wirsching S, Hilbert K et al. Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. Front Bioeng Biotechnol. 2022;10.","DOI":"10.3389\/fbioe.2022.993298"},{"key":"3840_CR178","doi-asserted-by":"crossref","unstructured":"Schulze RJ, Strom SC, Nyberg SL. From pain to gain: leveraging acetaminophen in hepatocyte transplantation for phenylketonuria. Hepatology. 2023.","DOI":"10.1097\/HEP.0000000000000713"},{"key":"3840_CR179","doi-asserted-by":"crossref","unstructured":"Vonada A, Wakefield L, Martinez M, Harding CO, Grompe M, Tiyaboonchai A. Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation. Hepatology. 2023.","DOI":"10.1101\/2023.08.27.554228"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03840-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T18:03:30Z","timestamp":1749146610000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03840-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":179,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3840"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03840-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}